Nepanizil (Donepezil Hydrochloride)

Donepezil, the active ingredient in Nepanizil, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of mild to moderate Alzheimer’s disease in adult patients, helping to improve cognition and daily functioning.

GNH USA supplies Nepanizil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for healthcare providers across multiple markets.

Donepezil is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

- Alzheimer’s disease (mild to moderate): improves cognitive function and daily living activities. - Parkinson’s disease dementia: helps enhance attention and memory in patients. - Dementia with Lewy bodies: may reduce cognitive fluctuations and improve alertness.

Donepezil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Insomnia - Muscle cramps - Fatigue - Loss of appetite

Serious or Rare Side Effects: - Bradycardia or other cardiac conduction abnormalities - Severe gastrointestinal bleeding or ulceration - Hepatic injury - Seizures - Atrial fibrillation - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Donepezil, clinicians should consider several safety precautions.

- Cardiac history: assess for bradyarrhythmias before initiation. - Gastrointestinal disorders: monitor for ulcer disease or bleeding risk. - Respiratory conditions: use cautiously in patients with asthma or COPD. - Hepatic impairment: adjust use in severe liver dysfunction. - Concomitant cholinergic drugs: avoid additive effects. - Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Donepezil can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticholinergic agents: may reduce therapeutic effect of Donepezil. - Certain antiarrhythmics (e.g., quinidine): can increase cardiac conduction abnormalities. - Strong CYP2D6 inhibitors (e.g., fluoxetine): may raise Donepezil plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: increase risk of gastrointestinal bleeding. - Beta‑blockers: may exacerbate bradycardia. - Other cholinesterase inhibitors: additive cholinergic effects.